Rockwell Medical, Inc. (RMTI)
USD 1.23
(13.89%)
USD 1.23
(13.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.43 Million USD | 58.99% |
| 2022 | -20.57 Million USD | 41.26% |
| 2021 | -35.03 Million USD | -9.71% |
| 2020 | -31.93 Million USD | -2.75% |
| 2019 | -31.07 Million USD | 3.26% |
| 2018 | -32.12 Million USD | -23.94% |
| 2017 | -25.92 Million USD | -30.9% |
| 2016 | -19.8 Million USD | -37.33% |
| 2015 | -14.42 Million USD | 32.38% |
| 2014 | -21.32 Million USD | 56.28% |
| 2013 | -48.78 Million USD | 9.7% |
| 2012 | -54.02 Million USD | -151.91% |
| 2011 | -21.44 Million USD | -699.16% |
| 2010 | -2.68 Million USD | 51.22% |
| 2009 | -5.5 Million USD | 30.05% |
| 2008 | -7.86 Million USD | -111.46% |
| 2007 | -3.71 Million USD | 18.71% |
| 2006 | -4.57 Million USD | -6056.38% |
| 2005 | 76.8 Thousand USD | -63.69% |
| 2004 | 211.52 Thousand USD | 4258.58% |
| 2003 | 4853.00 USD | 100.49% |
| 2002 | -980.71 Thousand USD | 37.89% |
| 2001 | -1.57 Million USD | -55.3% |
| 2000 | -1.01 Million USD | 7.56% |
| 1999 | -1.1 Million USD | 42.11% |
| 1998 | -1.9 Million USD | 0.0% |
| 1997 | -1.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.73 Million USD | -14.48% |
| 2024 Q2 | 343 Thousand USD | 119.82% |
| 2023 FY | -8.43 Million USD | 58.99% |
| 2023 Q4 | -1.51 Million USD | 19.23% |
| 2023 Q1 | -2.46 Million USD | 10.68% |
| 2023 Q2 | -3.3 Million USD | -34.35% |
| 2023 Q3 | -1.87 Million USD | 43.36% |
| 2022 Q1 | -7.69 Million USD | 13.9% |
| 2022 Q2 | -5.45 Million USD | 29.18% |
| 2022 Q3 | -4.67 Million USD | 14.31% |
| 2022 Q4 | -2.75 Million USD | 41.05% |
| 2022 FY | -20.57 Million USD | 41.26% |
| 2021 Q1 | -7.75 Million USD | 10.52% |
| 2021 Q3 | -7.58 Million USD | 9.75% |
| 2021 Q4 | -8.94 Million USD | -17.94% |
| 2021 Q2 | -8.4 Million USD | -8.36% |
| 2021 FY | -35.03 Million USD | -9.71% |
| 2020 Q2 | -6.89 Million USD | 13.67% |
| 2020 FY | -31.93 Million USD | -2.75% |
| 2020 Q4 | -8.66 Million USD | -17.86% |
| 2020 Q3 | -7.35 Million USD | -6.64% |
| 2020 Q1 | -7.98 Million USD | -9.33% |
| 2019 Q2 | -10.29 Million USD | -18.6% |
| 2019 Q1 | -8.67 Million USD | 7.44% |
| 2019 FY | -31.07 Million USD | 3.26% |
| 2019 Q4 | -7.3 Million USD | 7.04% |
| 2019 Q3 | -7.85 Million USD | 23.68% |
| 2018 Q4 | -9.37 Million USD | -88.66% |
| 2018 Q3 | -4.96 Million USD | 59.37% |
| 2018 FY | -32.12 Million USD | -23.94% |
| 2018 Q1 | -6.52 Million USD | 27.77% |
| 2018 Q2 | -12.23 Million USD | -87.32% |
| 2017 FY | -25.92 Million USD | -30.9% |
| 2017 Q4 | -9.03 Million USD | -78.75% |
| 2017 Q3 | -5.05 Million USD | 28.6% |
| 2017 Q2 | -7.08 Million USD | -49.37% |
| 2017 Q1 | -4.74 Million USD | 6.18% |
| 2016 Q1 | -4.82 Million USD | 16.39% |
| 2016 FY | -19.8 Million USD | -37.33% |
| 2016 Q4 | -5.05 Million USD | -10.76% |
| 2016 Q2 | -5.36 Million USD | -11.13% |
| 2016 Q3 | -4.56 Million USD | 14.88% |
| 2015 Q2 | -2.53 Million USD | 31.42% |
| 2015 Q4 | -5.76 Million USD | -138.97% |
| 2015 FY | -14.42 Million USD | 32.38% |
| 2015 Q1 | -3.69 Million USD | 42.05% |
| 2015 Q3 | -2.41 Million USD | 4.82% |
| 2014 Q2 | -3.17 Million USD | 59.38% |
| 2014 Q4 | -6.38 Million USD | -60.89% |
| 2014 Q3 | -3.96 Million USD | -25.15% |
| 2014 Q1 | -7.8 Million USD | 6.32% |
| 2014 FY | -21.32 Million USD | 56.28% |
| 2013 Q1 | -15.37 Million USD | -12.48% |
| 2013 FY | -48.78 Million USD | 9.7% |
| 2013 Q4 | -8.33 Million USD | 36.92% |
| 2013 Q3 | -13.2 Million USD | -11.34% |
| 2013 Q2 | -11.86 Million USD | 22.86% |
| 2012 Q2 | -11.9 Million USD | -12.67% |
| 2012 Q4 | -13.67 Million USD | 23.51% |
| 2012 FY | -54.02 Million USD | -151.91% |
| 2012 Q1 | -10.56 Million USD | -18.03% |
| 2012 Q3 | -17.87 Million USD | -50.15% |
| 2011 FY | -21.44 Million USD | -699.16% |
| 2011 Q4 | -8.95 Million USD | -77.57% |
| 2011 Q3 | -5.04 Million USD | -11.09% |
| 2011 Q2 | -4.53 Million USD | -55.83% |
| 2011 Q1 | -2.91 Million USD | -75.09% |
| 2010 Q3 | -743.35 Thousand USD | -735.8% |
| 2010 Q1 | -393.68 Thousand USD | 28.39% |
| 2010 Q2 | 116.91 Thousand USD | 129.7% |
| 2010 FY | -2.68 Million USD | 51.22% |
| 2010 Q4 | -1.66 Million USD | -123.75% |
| 2009 Q1 | -1.71 Million USD | 43.44% |
| 2009 Q4 | -549.78 Thousand USD | 63.86% |
| 2009 Q2 | -1.71 Million USD | 0.05% |
| 2009 FY | -5.5 Million USD | 30.05% |
| 2009 Q3 | -1.52 Million USD | 11.26% |
| 2008 FY | -7.86 Million USD | -111.46% |
| 2008 Q1 | -1.21 Million USD | -4.07% |
| 2008 Q4 | -3.03 Million USD | -20.78% |
| 2008 Q2 | -1.11 Million USD | 8.28% |
| 2008 Q3 | -2.51 Million USD | -126.22% |
| 2007 FY | -3.71 Million USD | 18.71% |
| 2007 Q3 | -432.91 Thousand USD | 9.17% |
| 2007 Q2 | -476.62 Thousand USD | 71.05% |
| 2007 Q1 | -1.64 Million USD | -42.55% |
| 2007 Q4 | -1.16 Million USD | -168.61% |
| 2006 FY | -4.57 Million USD | -6056.38% |
| 2006 Q3 | -1.62 Million USD | -7.46% |
| 2006 Q1 | -289.21 Thousand USD | -5.54% |
| 2006 Q4 | -1.15 Million USD | 28.77% |
| 2006 Q2 | -1.5 Million USD | -421.77% |
| 2005 Q2 | 85.45 Thousand USD | -21.75% |
| 2005 Q3 | 156.17 Thousand USD | 82.76% |
| 2005 Q4 | -274.04 Thousand USD | -275.47% |
| 2005 FY | 76.8 Thousand USD | -63.69% |
| 2005 Q1 | 109.21 Thousand USD | 857.69% |
| 2004 Q2 | 54.62 Thousand USD | -31.9% |
| 2004 Q4 | 11.4 Thousand USD | -82.53% |
| 2004 FY | 211.52 Thousand USD | 4258.58% |
| 2004 Q1 | 80.21 Thousand USD | -19.8% |
| 2004 Q3 | 65.27 Thousand USD | 19.5% |
| 2003 Q4 | 100.02 Thousand USD | 17.88% |
| 2003 Q2 | -93.23 Thousand USD | -7.42% |
| 2003 Q1 | -86.79 Thousand USD | -19.14% |
| 2003 FY | 4853.00 USD | 100.49% |
| 2003 Q3 | 84.85 Thousand USD | 191.01% |
| 2002 Q3 | -182.85 Thousand USD | 51.73% |
| 2002 Q4 | -72.84 Thousand USD | 60.16% |
| 2002 Q1 | -346.21 Thousand USD | 27.54% |
| 2002 FY | -980.71 Thousand USD | 37.89% |
| 2002 Q2 | -378.79 Thousand USD | -9.41% |
| 2001 Q1 | -285.68 Thousand USD | -138.07% |
| 2001 FY | -1.57 Million USD | -55.3% |
| 2001 Q4 | -477.82 Thousand USD | -3.91% |
| 2001 Q3 | -459.84 Thousand USD | -29.26% |
| 2001 Q2 | -355.74 Thousand USD | -24.52% |
| 2000 Q3 | -307.08 Thousand USD | 12.68% |
| 2000 Q2 | -351.66 Thousand USD | -47.73% |
| 2000 Q1 | -238.05 Thousand USD | -138.05% |
| 2000 Q4 | -120 Thousand USD | 60.92% |
| 2000 FY | -1.01 Million USD | 7.56% |
| 1999 Q1 | -400 Thousand USD | -33.33% |
| 1999 Q4 | -100 Thousand USD | 66.67% |
| 1999 Q3 | -300 Thousand USD | 25.0% |
| 1999 FY | -1.1 Million USD | 42.11% |
| 1999 Q2 | -400 Thousand USD | 0.0% |
| 1998 Q4 | -300 Thousand USD | 40.0% |
| 1998 FY | -1.9 Million USD | 0.0% |
| 1998 Q1 | -500 Thousand USD | -25.0% |
| 1998 Q2 | -500 Thousand USD | 0.0% |
| 1998 Q3 | -500 Thousand USD | 0.0% |
| 1997 Q4 | -400 Thousand USD | 0.0% |
| 1997 FY | -1.9 Million USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | 95.967% |
| Theratechnologies Inc. | -23.95 Million USD | 64.774% |
| Safety Shot Inc | -15.08 Million USD | 44.05% |
| Cosmos Health Inc. | -18.54 Million USD | 54.489% |
| Cronos Group Inc. | -73.96 Million USD | 88.59% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.158% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 80.002% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 270.657% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -36.929% |
| ProPhase Labs, Inc. | -16.78 Million USD | 49.714% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -74.54% |
| Dynavax Technologies Corporation | -6.38 Million USD | -32.086% |
| Radius Health, Inc. | -25.79 Million USD | 67.279% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -172.355% |
| Alvotech | -551.73 Million USD | 98.47% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -87.282% |
| Alpha Teknova, Inc. | -36.78 Million USD | 77.055% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 93.958% |
| SCYNEXIS, Inc. | 67.04 Million USD | 112.588% |
| Harrow Health, Inc. | -24.41 Million USD | 65.43% |
| Biofrontera Inc. | -20.13 Million USD | 58.08% |
| DURECT Corporation | -27.62 Million USD | 69.45% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 741.261% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 144.938% |
| OptiNose, Inc. | -35.48 Million USD | 76.217% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 135.286% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -7.23% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -34.394% |
| SIGA Technologies, Inc. | 68.06 Million USD | 112.398% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 170.249% |
| Shineco, Inc. | -22.44 Million USD | 62.408% |
| Phibro Animal Health Corporation | 2.41 Million USD | 449.296% |
| Procaps Group S.A. | 42.54 Million USD | 119.838% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 17.893% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -96.172% |
| Viatris Inc. | 54.7 Million USD | 115.428% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -87.282% |
| Incannex Healthcare Limited | -18.45 Million USD | 54.282% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 46.737% |
| Tilray Brands, Inc. | -244.98 Million USD | 96.555% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 117.525% |
| PetIQ, Inc. | 2.13 Million USD | 496.011% |
| Silver Spike Investment Corp. | 7.34 Million USD | 214.971% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 103.38% |
| Journey Medical Corporation | -3.85 Million USD | -119.024% |
| Alimera Sciences, Inc. | -20.13 Million USD | 58.082% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -3.379% |
| Assertio Holdings, Inc. | -331.94 Million USD | 97.458% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -28.005% |
| Embecta Corp. | 70.4 Million USD | 111.987% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 57.926% |
| Procaps Group, S.A. | 42.54 Million USD | 119.838% |
| PainReform Ltd. | -9.34 Million USD | 9.685% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 94.735% |
| Hempacco Co., Inc. | -13.12 Million USD | 35.708% |
| Talphera, Inc. | -18.39 Million USD | 54.128% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 120.114% |
| Alvotech | -551.73 Million USD | 98.47% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 102.583% |
| Kamada Ltd. | 8.28 Million USD | 201.871% |
| Indivior PLC | 2 Million USD | 521.95% |
| Currenc Group, Inc. | -15.3 Million USD | 44.867% |
| Evoke Pharma, Inc. | -7.79 Million USD | -8.299% |
| Flora Growth Corp. | -57.03 Million USD | 85.204% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 57.926% |
| Evolus, Inc. | -61.68 Million USD | 86.319% |
| HUTCHMED (China) Limited | 100.78 Million USD | 108.374% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 106.135% |
| Akanda Corp. | -32.27 Million USD | 73.853% |